The intriguing patterns of tumor response to trabectedin

Expert Review of Anticancer Therapy

Volumn 13, Issue 6 SUPPL., 2013, Pages 21-24

  Sanfilippo, Roberta ^a   Casali, Paolo G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

choi criteria; dimensional response; immunomodulation; leiomyosarcoma; myxoid liposarcoma; nondimensional response; response criteria; targeted therapy; trabectedin

Indexed keywords

DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; TRABECTEDIN;

ANTIINFLAMMATORY ACTIVITY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER MORPHOLOGY; CANCER PATIENT; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; LIPOSARCOMA; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; PROGRESSION FREE SURVIVAL; RETROPERITONEAL SARCOMA; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; UTERUS MYOMA; UTERUS SARCOMA;

ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; FEMALE; HUMANS; LEIOMYOSARCOMA; LIPOSARCOMA, MYXOID; MOLECULAR TARGETED THERAPY; SARCOMA; TETRAHYDROISOQUINOLINES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; UTERINE NEOPLASMS;

EID: 84877252943     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.51     Document Type: Conference Paper

References (16)

1. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized Phase II study of two different schedules. J. Clin. Oncol. 27(25), 4188-4196 (2009).
2. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8(7), 595-602 (2007).
3. von Mehren M. Trabectedin - a targeted chemotherapy? Lancet Oncol. 8(7), 565-567 (2007).
4. Narendra S, Valente A, Tull J et al. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma - assay validation and clinical experience. Diagn. Mol. Pathol. 20(4), 218-224 (2011).
5. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur. J. Cancer 41(18), 2853-2860 (2005).
6. Katz D, Boonsirikamchai P, Choi H et al. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. Clin. Sarcoma Res. 2(1), 2 (2012).
7. Sanfilippo R, Grosso F, Virdis E et al. Rechallenge with trabectedin in patients with responding myxoid liposarcoma. J. Clin. Oncol. 27(Suppl. 15S), 10575 (2009).
8. Forni C, Minuzzo M, Virdis E et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol. Cancer Ther. 8(2), 449-457 (2009).
9. Blay JY, Leahy MG, Bui BN et al. Randomized multicenter Phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS). J. Clin. Oncol. 30(Suppl.), Abstract TPS10101 (2012).
10. Verweij J. Other endpoints in screening studies for soft tissue sarcomas. Oncologist 13(Suppl. 2), 27-31 (2008).
11. Sanfilippo R, Grosso F, Jones RL et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol. Oncol. 123(3), 553-556 (2011).
12. Germano G, Frapolli R, Simone M et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 70(6), 2235-2244 (2010).
13. Karnofsky DA. Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin. Pharmacol. Ther. 2(6), 709-712 (1961).
14. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5(6), 649-655 (1982).
15. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009).
16. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 13(Suppl. 2), 4-7 (2008).